

Resource Summary Report

Generated by [RRID](#) on Jul 30, 2026

Oct-4A (C30A3) Rabbit mAb (Alexa Fluor 488 Conjugate)

RRID:AB_10693303

Type: Antibody

Proper Citation

Cell Signaling Technology Cat# 5177, RRID:AB_10693303

Antibody Information

URL: http://antibodyregistry.org/AB_10693303

Proper Citation: Cell Signaling Technology Cat# 5177, RRID:AB_10693303

Target Antigen: Oct-4A (C30A3) Rabbit mAb (Alexa Fluor 488 Conjugate)

Host Organism: rabbit

Clonality: monoclonal

Comments: Applications: IF-IC, F

Antibody Name: Oct-4A (C30A3) Rabbit mAb (Alexa Fluor 488 Conjugate)

Description: This monoclonal targets Oct-4A (C30A3) Rabbit mAb (Alexa Fluor 488 Conjugate)

Target Organism: h, m, mouse, human

Antibody ID: AB_10693303

Vendor: Cell Signaling Technology

Catalog Number: 5177

Record Creation Time: 20250819T212717+0000

Record Last Update: 20250819T230037+0000

Ratings and Alerts

No rating or validation information has been found for Oct-4A (C30A3) Rabbit mAb (Alexa Fluor 488 Conjugate).

No alerts have been found for Oct-4A (C30A3) Rabbit mAb (Alexa Fluor 488 Conjugate).

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 13 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Patel A, et al. (2022) Efficient Cas9-based Genome Editing Using CRISPR Analysis Webtools in Severe Early-onset-obesity Patient-derived iPSCs. Current protocols, 2(8), e519.

Iannello G, et al. (2021) Generation of the iPSC line CUIMCi003-A derived from a patient with severe early onset obesity. Stem cell research, 54, 102432.

Iannello G, et al. (2021) Derivation and characterization of the induced pluripotent stem cell line CUIMCi004-A from a patient with a novel frameshift variant in exon 18a of OCRL. Stem cell research, 59, 102635.

Patel A, et al. (2020) Establishment and characterization of two iPSC lines derived from healthy controls. Stem cell research, 47, 101926.

Riera M, et al. (2019) Generation of an induced pluripotent stem cell line (FRIMOi002-A) from a retinitis pigmentosa patient carrying compound heterozygous mutations in USH2A gene. Stem cell research, 35, 101386.

Ihry RJ, et al. (2019) Genome-Scale CRISPR Screens Identify Human Pluripotency-Specific Genes. Cell reports, 27(2), 616.

Riera M, et al. (2019) Establishment and characterization of an iPSC line (FRIMOi001-A) derived from a retinitis pigmentosa patient carrying PDE6A mutations. Stem cell research, 35, 101385.

Riera M, et al. (2019) Generation of two iPS cell lines (FRIMOi003-A and FRIMOi004-A) derived from Stargardt patients carrying ABCA4 compound heterozygous mutations. Stem cell research, 36, 101389.

Domingo-Prim J, et al. (2019) Establishment of an induced pluripotent stem cell line (FRIMOi005-A) derived from a retinitis pigmentosa patient carrying a dominant mutation in RHO gene. Stem cell research, 38, 101468.

Domingo-Prim J, et al. (2019) Generation of Best disease-derived induced pluripotent stem cell line (FRIMOi006-A) carrying a novel dominant mutation in BEST1 gene. Stem

cell research, 40, 101570.

Domingo-Prim J, et al. (2019) Generation of an induced pluripotent stem cell line (FRIMOi007-A) derived from an incomplete achromatopsia patient carrying a novel homozygous mutation in PDE6C gene. Stem cell research, 40, 101569.

Baulier E, et al. (2018) Generation of a human Ocular Albinism type 1 iPSC line, SEli001-A, with a mutation in GPR143. Stem cell research, 33, 274.

Anderson RH, et al. (2018) Generation of a CLTA reporter human induced pluripotent stem cell line, CRMi001-A-1, using the CRISPR/Cas9 system to monitor endogenous clathrin trafficking. Stem cell research, 33, 95.